MOYA Bio is developing a novel class of tumor immune conditioning agents.

Scientific approach

FAT10 pathway inhibition has been shown to drive anti-tumor activity by induction of apoptosis and by modulating the tumor microenvironment to be more accommodating to immunotherapies.

MOYA Bio’s translational data demonstrates a correlation between FAT10 down-regulation, increased T cell infiltration into the tumor microenvironment and inhibition of tumor growth. 

link to Moya Bio page

Indications

Non-small Cell Lung Carcinoma

The global NSCLC market is growing rapidly and is expected to exceed $15B by 2024 

Team

Yifat Merbl, PhD – Inventor

Dr. Merbl received her PhD from Harvard University and is a Principal Investigator at the Weizmann Institute of Science, Department of Immunology. She is an expert in the fields of Biochemical Immunology and Cell Biology where she developed several advanced high-throughput immuno-proteomic technologies, published in top peer-reviewed journals. She is a co-founder of PTM Biosciences.

Eyal Ben Ami, PhD – CSO

Dr. Ben Ami received his PhD in Immunology from the Technion, and completed a research fellowship at UPMC in Paris. Eyal previously held various leadership positions at ImmunoBrain Therapies and BioLineRx, leading the development of immunotherapy programs from early preclinical stages through clinical translation.

Scroll to top